cyclophosphamide
cyclophosphamide: sourced relationships with 1 company · 365 clinical trials tracked · 1 FDA decision.
cyclophosphamide evidence translation
What we can confirm
1 FDA record · 365 tracked trials
What it means
What to watch
Prepared research question
How could cyclophosphamide → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 15 study sponsors
Related indications
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) Reported 2024-10-29 · Current development: unknownSource | Approved |
| NEXUS BIOPHARMA INC (NEXS) Reported 2024-10-29 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (365)showing 10 most recent
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Primary endpoint: Incidence of adverse events
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)
Primary endpoint: The absolute change from baseline in Forced Vital Capacity (FVC) in mL
A Phase I Study of Single Agent Epcoritamab Followed by Epcoritamab Plus Pola-R-Mini-CHP for Elderly/Unfit Patients With Previously Untreated DLBCL
Primary endpoint: Progression free survival
A Phase I Trial of Lymphodepletion Intensification With Low Dose Total Body Irradiation With Dose Expansion for Standard-of-Care Tisagenlecleucel in Patients With Large B-Cell Lymphoma
Primary endpoint: Dose-limiting toxicities
A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Primary endpoint: Number of Participants With Adverse Events
A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)
Primary endpoint: Dose limiting toxicities (Safety run-in: Cohort A)
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Primary endpoint: To assess the safety of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation for pediatric patients with relapsed/refractory CD19+ B-cell malignancies.
A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial
Primary endpoint: Left Ventricular Ejection Fraction (LVEF)
A Multicenter, Phase 1, Safety and Tolerability Study of CC-97540 (BMS- 986353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
Primary endpoint: To evaluate the safety and tolerability of CC-97540 (BMS-986353) in participants with anti-AQP4 antibody positive NMO as determined by the proportion of patients experiencing DLTs
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Primary endpoint: GVHD-free and rejection free survival (GRFS)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with cyclophosphamide?
cyclophosphamide has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.
How many clinical trials involve cyclophosphamide?
BioSniper tracks 365 clinical trials involving cyclophosphamide.
What is cyclophosphamide's latest FDA decision?
The most recent tracked FDA decision for cyclophosphamide is Approval for 1 INDICATIONS AND USAGE Cyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 ) 1.1 Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and , dated October 29, 2024.